

Interaction Report

Report ID:

Date Produced:

06 June 2025

Antiretroviral Treatment

Co-medications

Efavirenz (EFV)

Alprazolam

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Efavirenz (EFV) + Alprazolam

Coadministration has not been studied. Alprazolam is metabolised mainly by CYP3A4. Efavirenz, an inducer of CYP3A4, could potentially decrease alprazolam exposure. Monitor clinical effect and withdrawal symptoms.